Items tagged with Treatment
Call for expressions of interest: Systematic reviews on hepatitis B and hepatitis C co-infection with TB and MDR/RR-TB and the effects of co-administration of MDR/RR-TB and hepatitis C treatment (post)
The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.
WHO announces updated definitions of TB treatment outcomes (post)
8 April 2021, Geneva | The definitions of tuberculosis (TB) treatment outcomes have been revised by the World Health Organization (WHO)’s Global Tuberculosis Programme. New definitions of treatment outcomes will standardise the assessment of treatment outcomes for all TB patients and all treatment regimens regardless of drug-resistance status, type of drugs used or duration of treatment.
Update of the WHO guidance on the treatment of drug susceptible TB (post)
The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the treatment of drug susceptible tuberculosis (TB).
MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs (post)
New Delhi/Geneva, 20 April 2021 – Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. If the government is willing to issue the ‘compulsory licenses,’ it would increase access to the newer TB drugs bedaquiline and delamanid for people with multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB in India. The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) supports the court petition and urges the Indian government to take this critical step that would allow price-lowering competition among generic manufacturers for drug-resistant (DR) TB medicines in India.
Pulmonary TB: Adjunctive therapies may enhance lung function recovery (post)
Host-directed adjunctive therapies everolimus and CC-11050 are safe and reasonably well-tolerated in adults with pulmonary tuberculosis infection, according to results of a study published in the journal Lancet Respiratory Medicine. In addition, the 2 therapies may also improve lung function recovery.
Tailor-made therapy of multidrug-resistant TB (post)
The successful treatment of multidrug-resistant tuberculosis requires clarification in advance as to which antibiotics the pathogens are resistant to. Classic testing in the laboratory is very time-consuming and delays the start of therapy. Researchers from the Research Center Borstel, the Leibniz Lung Center, and the German Center for Infection Research (DZIF) have now prepared a catalogue of all mutations in the genome of tuberculosis bacteria and on the basis of a genome sequencing can quickly and cheaply predict which medicines are most effective for tuberculosis treatment. The results of this work were published in the professional journal Clinical Infectious Diseases.
TB therapy is a new risk factor for recurrent C diff (post)
Treatment with rifampin shows it can increase the chances for recurrent Clostridium difficile (C diff) infection according to investigators in Mexico.
Pravastatin may have protective effect against active TB infection (post)
Risk for active tuberculosis (TB) may be reduced with the use of statins. This finding was published in a letter to the editor in the Journal of Infectious Diseases.1
Performance of TB biomarker for targeted preventative therapy (post)
An RNA signature of tuberculosis, RISK11, was used to discriminate between individuals with prevalent tuberculosis or progression to incident tuberculosis and individuals who remained healthy, according to a study in The Lancet Infectious Diseases. However, the use of 3 months of once-weekly high-dose isoniazid and rifapentine (3HP) to treat signature-positive individuals did not reduce progression to tuberculosis over 15 months.
Development of updated WHO guidelines on the management of TB in children and adolescents (post)
The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the management of tuberculosis (TB) in children and adolescents.
Page 57 of 106 · Total posts: 0
←First 56 57 58 Last→